Option chain shows key data for Azitra's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Azitra.

Azitra (AMEX:AZTR) Stock, Option Chain

Anitra

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Mountain,View,,Ca,,Usa,-,Feb,25,,2020:,The,Coursera

News

Pre-Market Outlook

Markets

Movers

AGMH

AZTR

BCTX

COUR

CPOP

GILD

GOOGL

INTC

JZXN

OMEX

PRPO

SHCO

TVRD

WEST

Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket

5 Stocks To Watch Heading Into Thursday

Earnings

Equities

Eurozone

Commodities

Intraday Update

Trading Ideas

OMGA

QNTM

VLCN

US Stocks Mixed; PepsiCo Posts Downbeat Sales

Palantir,Technologies,Japan,Logo,,Tokyo,,Japan,2024,Sep.15

AREB

EVAX

HCWB

ILMN

IVVD

KAPA

PDLB

PLTR

REBN

TNXP

UOKA

XPEV

ZONE

Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

Azitra Inc

Press Releases

Azitra, Inc. to Present at The Microcap Conference

Azitra, Inc. to Present at the BIO CEO & Investor Conference

Offerings

Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock

Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

Azitra to Present at Microbiome Times Partnering Forum

Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline

Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025

Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

180 Life Sciences

Azitra

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galecto

GRI Bio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Palisade Bio

Polyrizon

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

SILO Pharma

Soligenix

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Tharimmune

Theriva Biologics

Xenetic Biosciences

Comments

Azitra

Azitra (AZTR) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell